Amgen Inc.

Amgen Inc. is a biotechnology company focused on developing biologic medicines aimed at treating serious diseases with limited treatment options. Amgen Inc. develops innovative therapies in biotechnology, founded in 1985 and headquartered in Thousand Oaks, California, US.

The company was co-founded by Jenna Crenshaw, Kate BA, and Le ha, with Bob Bradway serving as CEO. Amgen has remained committed to its core mission since its inception, without significant pivots in its business strategy. Amgen specializes in the development and manufacturing of biologic medicines for serious diseases, offering therapies that target oncology, cardiovascular health, inflammation, and metabolic bone diseases. These therapies utilize living cells to produce biologics, providing healthcare providers, hospitals, and clinics with effective treatment alternatives across global markets, including North America, Europe, and Asia.

In the most recent fiscal year, Amgen reported a revenue of USD 32. 03 bn, with an EBITDA of USD 12. 85 bn. The company generates revenue primarily through its proprietary biologic medicines sold to healthcare institutions, pharmacies, and directly to consumers, employing a robust B2B pricing model that reflects the value of its offerings.

Amgen plans to leverage its recent funding to support the development of new products aimed at enhancing its therapy portfolio. The company is focused on expanding into new markets, particularly in Asia and Europe, by 2026, to increase its global footprint. By strategically investing in R&D and establishing partnerships within the healthcare sector, Amgen aims to address unmet medical needs and enhance access to its biologic therapies.